Invivyd Names Marc Elia CEO as Key COVID Antibody Trials Near Completion
Event summary
- Marc Elia, Chairman of Invivyd’s Board, appointed as CEO effective September 1, 2026.
- Ajay Royan, Founder of Mithril Capital, becomes Lead Independent Director.
- Ian Sheffield, founder of North Country Holdings, joins the Board as an independent director.
- Top-line data from VYD2311 trials (DECLARATION and LIBERTY) expected by end of Q3 2026.
- Invivyd exploring multiple regulatory pathways for VYD2311, including traditional and accelerated approval.
The big picture
Invivyd’s leadership transition and impending trial results come at a critical juncture for COVID-19 prevention, as the company positions VYD2311 as a next-generation monoclonal antibody. The move to appoint Marc Elia as CEO underscores a focus on scaling antibody technologies beyond COVID, while the trial outcomes will determine the near-term regulatory and commercial trajectory. The biotech sector continues to grapple with evolving viral threats, making Invivyd’s adaptive strategy a key test case for monoclonal antibody platforms.
What we're watching
- Regulatory Pathway
- Whether Invivyd’s flexible approach to BLA submission (traditional or accelerated) will expedite VYD2311’s availability.
- Clinical Trial Outcomes
- The statistical power and event accumulation in the DECLARATION study, which could influence FDA review.
- Leadership Impact
- How Marc Elia’s dual role as Chairman and CEO will shape Invivyd’s strategic direction and execution.